US FDA clears IND for NTI164
Filed with ASX · · 3 pages · English
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- NTI secures Notices of Allowance for US patent applications
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents
- Approval received for NTI164 Phase 3 Clinical Study in ASD
Later from Neurotech International
- Neurotech secures $3.15 million R&D tax incentive loan
- Receipt of Binding Commitments for $4.5m Placement
- NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International